Evidence map›Paper›PMID 20156770›Full record

ArticleEuropean journal of medical research2009

Clinical implications of serum thrombomodulin in PR3-ANCA-associated vasculitis.

K Zycinska, K A Wardyn, T M Zielonka, R Krupa, W Lukas

Open access · bronzeAbstract read
In one paragraph

Article in European journal of medical research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Thrombosis risk factors in PIK3CA-related overgrowth spectrum and Proteus syndrome.American journal of medical genetics. Part C, Seminars in medical genetics · 2019
    Article
  5. Review
  6. Article
  7. Thrombomodulin and the vascular endothelium: insights into functional, regulatory, and therapeutic aspects.American journal of physiology. Heart and circulatory physiology · 2013
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

K ZycinskaPrimary Systemic Vasculitis Outpatient Clinic, Department of Family Medicine, Internal and Metabolic Diseases, Warsaw Medical University, Warsaw, Poland. kzycinska@poczta.fm
K A Wardyn
T M Zielonka
R Krupa
W Lukas
Medical University of Warsaw · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVascular injury is the main mechanism in pathophysiology of PR3-ANCA-associated vasculitis. Soluble serum thrombomodulin (sTM) is a membrane-bound receptor for thrombin expressed by vascular endothelial cells. -

objectiveThe aim of study was to determine the blood levels of sTM in patients with PR3-ANCA-associated vasculitis. MATERIAL AND

methodsTwenty five patients with Wegener's granulomatosis (WG), 13 with generalized WG and 12 with limited WG, with histologically proven disease, and 15 healthy subjects as a control were investigated. An ELISA for detection of sTM and PR3-ANCA was performed. The disease activity was evaluated according to BVAS and DEI indexes.

resultsSignificant increases in sTM were found in both active generalized and limited active WG compared with control values: 108 +/- 12, 56 +/- 2, and 12 +/- 4 ng/ml, respectively. Elevated ANCA titer correlated with disease activity, but more weakly than sTM levels did. Elevated sTM concentration is a result of vascular endothelial injury in the course of PR3-ANCA associated vasculitis.

conclusionsSoluble serum thrombomodulin is a promising, both diagnostic and therapeutic, marker of endothelial cell injury in relation to disease activity and progression in autoimmune disorders, reflecting the degree of endothelial cell damage.

Indexed as

AdultAgedAntibodies, Antineutrophil CytoplasmicFemaleGranulomatosis with PolyangiitisHumansMaleMiddle AgedThrombomodulinAntibodies, Antineutrophil CytoplasmicThrombomodulin

Identifiers

PMID20156770
PMCPMC3521377
OpenAlexW1963816735

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.